All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
2 warning events since 2017; the latest 2024-04-30.
From the record
Evotec SE's filings since 2017 show 2 warning events: a late-report notice (Form NT 10-K or NT 10-Q, 2 times, the latest 2024-04-30) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+12.3% a year over 6 filed years; profitable in 3 of 6.
From the record
Evotec SE's 6 filed years say what it did: revenue went from EUR 446 million in fiscal 2019 to EUR 797 million in fiscal 2024, up 12.3% a year; it rose in 5 of 5 years; it never fell from a peak; net income was positive in 3 of 6 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
Share count grew 2.1% a year. 0% of cash flow returned. Insiders: 0 sales, 0 purchases.
From the record
Over the 3 fiscal years to 2024-12-31, Evotec SE's diluted share count grew about 2.1% a year, and dividends and buybacks returned about 0% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 0 sales and 0 purchases of their own stock on the open market in the year to 2026-09-30 (their Form 4 filings).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they doing right now?
Is it financially healthy right now?
ROE -21%: lost 21¢ per shareholder dollar. Leverage 50%: owes 50¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2024-12-31, Evotec SE lost about 21 cents for every dollar of shareholders' money, and gross profitability: its products earned about 6 cents per dollar of everything the company owns. Leverage: it owed about 50 cents per dollar of assets, and net share issuance: its share count grew 0.2% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
top 41% of 315 in its family; net margin -24.6%.
From the record
Evotec SE's standing among 315 graded names in its industry family: revenue of EUR 797 million in fiscal 2024 is not ranked by size, since the family reports in another currency; a net margin of -24.6% ranks in the top 33%; revenue growth of 8.8% a year over the last 3 filed years ranks in the top 49% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
SI estimate 5.0/10, confidence 20 of 100 (family median).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Evotec SE's leadership is put at 5.0 of 10 with a confidence of 20 of 100, because it files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; no officer or director has filed a Form 3, 4 or 5 for it in the last fifteen months, so the years in charge cannot be read, so the desk assumes the typical reading of its industry family, the median of 371 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.
What are they set up to do next?
How much room does it have to grow?
bottom 24% of 273 in its family for room to expand.
From the record
Evotec SE's room to grow, from the newest filed statements (fiscal 2024): cash of EUR 306 million against debt of EUR 288 million leaves 1% of its assets as net cash, bottom 15% of its family; cash from operations less capital spending is -12.5% of revenue (top 33%); a gross margin of 14.4% (bottom 7%); research spending of 6.4% of revenue (bottom 8%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 45% of 306 in its family for growth drivers.
From the record
Evotec SE's growth drivers, from the filed years to fiscal 2024: revenue grew 8.8% a year over the last three filed years against 12.3% over all 6, slowing (bottom 47% of its family); the newest year grew 2% (bottom 42%); research spending grew -11% a year (bottom 29%); capital spending grew -0.4% a year (top 39%) (its annual reports). Evotec SE tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
bottom 22% of 233 in its family for expectations against reality.
From the record
Evotec SE's newest year against its own record: revenue of EUR 797 million in fiscal 2024 came in 9.3% below the EUR 879 million its prior three years' pace pointed to (bottom 39% of its family); net income of EUR 196 million against a prior three-year average of EUR 15 million (bottom 3%); a net margin of -24.6% against 0.3% before (bottom 25%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made